Long-term use of ultra-low-dose mifepristone for uterine leiomyoma control and safety discussion: A case report.

Abstract

RATIONALE:

In recent years, many clinical trials have used low-dose mifepristone to control uterine fibroids, some of which have achieved good results. However, according to the classic concept, long-term use of mifepristone could induce malignant transformation of the endometrium, and the effect of ultra-low-dose of mifepristone on uterine fibroids is still uncertain. Researchers are short on cases of uterine fibroids treated with mifepristone for long periods (more than a year).

PATIENT CONCERNS:

A 47-year-old woman went to the hospital because of anemia.

DIAGNOSES:

The patient was diagnosed with uterine leiomyoma.

INTERVENTIONS:

The patient refused the suggestion of surgery, she was continuously treated with an ultra-low-dose (12.5 mg per 5 days) of mifepristone monotherapy for 4 years.

OUTCOMES:

The uterine leiomyoma was stable, anemia and other symptoms disappeared, and the menstrual cycle, liver and kidney function, and tumor markers were normal.

LESSONS:

Judging from our case, long-term, ultra-low-dose mifepristone for uterine fibroids treatment was safe and more effective than conventional therapy.

• Authors: Guangdi Zhou, Qin Li
• Journal: Medicine (Medicine (Baltimore)) Vol. 101 Issue 52 Pg. e32413 (Dec 30 2022) ISSN: 1536-5964 [Electronic] United States
• PMID: 36595976 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• Mifepristone
• Hormone Antagonists

Topics

• Female
• Humans
• Middle Aged
• Mifepristone (therapeutic use)
• Uterine Neoplasms (drug therapy, pathology)
• Leiomyoma (drug therapy, pathology)
• Hormone Antagonists (therapeutic use)
• Menstrual Cycle